EKF Diagnostics Investor Announcements

EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2014.

EKF announce the appointment of David Toohey and Doris-Ann Williams MBE to the Board as Non-Executive Directors.

EKF Diagnostics the AIM listed point-of-care, central laboratory and molecular diagnostics business, provides the following trading update for the six months ended 30 June 2014.

EKF Diagnostics Holdings plc, announces the appointment of Dr Tito Bacarese-Hamilton to the Board of Directors of the Company, as Chief Technology Officer with immediate effect. 

Update to shareholders on reimbursement levels received by recently acquired Selah Genomics, Inc.

The Board of EKF is pleased to announce that the resolutions to acquire Selah Genomics and DiaSpect Medical were duly passed.

The open offer to qualifying participants has been over-subscribed.

EKF Diagnostics announces that it has entered into a conditional agreement to acquire Selah Genomics, Inc. and DiaSpect Medical AB.a Swedish based manufacturer of point-of-care haemoglobin analysers.

EKF Diagnostics announces its audited final results for the year ended 31 December 2013, a year of strong organic growth and improved earnings.

EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2013.